GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,488.00 DKK | -3.12% |
|
-4.09% | -30.95% |
| 12-11 | Genmab A/S - Special Call | |
| 12-09 | Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial | MT |
Chart calendar Genmab A/S
8f3c65.BYkxd-1GStaN1BnoWiojTNgxjoiikwQhB844N2ynEaM.YM1hI5UMEIbbgUqnYxMSDZYCyfzR-V1na55JeF2fVPQ95Xgzh3F4mr2LQA~57ce80de300723d1e84a8c6dfb102ee6
Upcoming events on Genmab A/S
Past events on Genmab A/S
| 11/12/2024 16:00 | R&D Day |
| 10/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:5124 |
| 10/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:4491 |
| 10/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:4480 |
| 09/12/2024 22:45 | American Society of Hematology Meeting - Abstract No:883 |
| 09/12/2024 22:45 | American Society of Hematology Meeting - Abstract No:867 |
| 09/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:3723 |
| 09/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:3231 |
| 09/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:3115 |
| 09/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:3110 |
| 09/12/2024 02:00 | American Society of Hematology Meeting - Abstract No:3106 |
| 08/12/2024 20:00 | American Society of Hematology Meeting - Abstract No:581 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1414 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1622 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:2349 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1734 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1737 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:2998 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1703 |
| 08/12/2024 01:30 | American Society of Hematology Meeting - Abstract No:1627 |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 8 482 8 376 1.26% | 14 595 14 068 3.75% | 16 474 16 380 0.58% | 21 171 | 24 715 | 28 940 |
|
EBITDA Million DKK | Released Forecast Spread | 3 266 3 111 4.98% | 6 719 6 371 5.46% | 5 616 5 721 -1.83% | 6 820 | 8 099 | 9 971 |
|
EBIT Million DKK | Released Forecast Spread | 3 018 2 960 1.96% | 6 357 6 008 5.81% | 5 321 5 398 -1.42% | 6 421 | 7 585 | 9 549 |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | 3 983 3 731 6.77% | 7 035 8 905 -21% | 5 637 6 236 -9.6% | 7 395 | 8 036 | 10 249 |
|
Net income Million DKK | Released Forecast Spread | 3 008 2 847 5.64% | 5 522 6 793 -18.71% | 4 352 4 989 -12.77% | 5 487 | 6 221 | 7 880 |
|
EPS DKK | Released Forecast Spread | 45,5 43,8 3.94% | 83,7 104 -19.22% | 66,0 76,2 -13.35% | 83,1 | 91,5 | 118 |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | - |
Quarterly results
| Fiscal Period | September | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 2 854 2 809 1.62% | 4 198 4 070 3.13% | 7 052 6 896 2.26% | 4 744 4 474 6.03% | 4 678 4 610 1.48% | 4 143 3 989 3.86% | 5 402 4 959 8.94% | 9 545 9 039 5.6% | 5 540 5 646 -1.89% | 6 343 | 4 846 | 6 062 | 6 416 | 6 306 |
|
EBITDA Million DKK | Released Forecast Spread | 458 583 -21.48% | 1 520 1 670 -8.96% | 1 978 2 145 -7.79% | 1 739 1 646 5.65% | 1 899 1 804 5.28% | 823 880 -6.45% | 1 571 | 2 627 2 412 8.91% | 2 129 1 847 15.25% | 2 040 | ||||
|
EBIT Million DKK | Released Forecast Spread | 437 527 -17.08% | 1 497 1 573 -4.85% | 1 934 1 977 -2.18% | 1 717 1 702 0.87% | 1 670 1 772 -5.73% | 801 832 -3.68% | 1 640 1 599 2.57% | 2 441 2 229 9.51% | 2 102 1 782 17.95% | 1 979 | 541 | 1 577 | 1 873 | 1 670 |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | 286 402 -28.85% | 1 723 1 602 7.57% | 2 009 1 927 4.26% | 2 702 1 774 52.33% | 926 1 888 -50.95% | 1 716 1 064 61.28% | 2 127 1 847 15.15% | 3 843 3 374 13.9% | 1 719 1 761 -2.38% | 1 976 | 227 | 1 352 | 1 523 | 1 768 |
|
Net income Million DKK | Released Forecast Spread | 226 397 -43.08% | 1 357 1 204 12.72% | 1 583 1 503 5.32% | 2 129 1 382 54.01% | 640 1 439 -55.52% | 1 325 833 59.07% | 1 408 1 426 -1.28% | 2 733 2 598 5.2% | 1 266 1 373 -7.77% | 1 514 | 182 | 1 082 | 1 218 | 1 414 |
|
EPS DKK | Released Forecast Spread | 3,43 5,07 -32.28% | 20,6 19,3 7.03% | 24,0 22,7 5.86% | 32,3 21,2 52.42% | 9,67 23,0 -57.93% | 20,2 12,8 57.63% | 21,7 22,8 -4.76% | 41,9 39,5 5.92% | 19,8 21,6 -8.41% | 21,9 | 8,97 | 22,6 | 24,2 | 26,7 |
| Announcement Date | 10/05/23 | 03/08/23 | 03/08/23 | 07/11/23 | 14/02/24 | 02/05/24 | 08/08/24 | 08/08/24 | 06/11/24 | - | - | - | - | - |
More events
Past sector events for Genmab A/S
| 09/12/2024 11:16 | LUMOSA THERAPEUTICS CO., LTD.: November 2024 Sales and Revenue Release |
| 05/12/2024 09:03 | PHARMAESSENTIA CORPORATION: November 2024 Sales and Revenue Release |
| 26/11/2024 21:00 | ARROWHEAD PHARMACEUTICALS, INC.: Q4 2024 Earnings Release |
| 24/11/2024 | ANAVEX LIFE SCIENCES CORP.: Q4 2024 Earnings Release (Projected) |
| 18/11/2024 12:00 | IMMATICS N.V.: Q3 2024 Earnings Release |
| 14/11/2024 21:01 | CELCUITY INC.: Q3 2024 Earnings Release |
| 14/11/2024 21:01 | ASCENDIS PHARMA A/S: Q3 2024 Earnings Release |
| 14/11/2024 13:00 | ANNEXON, INC.: Q3 2024 Earnings Release |
| 14/11/2024 09:09 | PHARMAESSENTIA CORPORATION: Q3 2024 Earnings Release |
| 13/11/2024 | PEPTRON, INC.: Q3 2024 Earnings Release |
Quarterly revenue - Rate of surprise
Net sales - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GMAB Stock
- Calendar Genmab A/S
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition